A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2600 participants.
Also called NCT06033950
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,600 participants
- Sponsor
- Registry
-
NCT06033950
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Brazil, Canada, Croatia, Czechia, Greece, Hungary, Italy, Japan, Poland, Spain, Sri Lanka, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT06033950. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-20 (actual); primary completion 2026-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
- Acronym
- FINALITY-HF
- Condition
- Heart Failure
- Intervention (Drug)
- Finerenone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Colorado Prevention Center
- Collaborator
- St. Luke's Hospital, Kansas City, Missouri
- Collaborator
- Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Record details
- Record id
cardio:ct-nct06033950- Content hash
e82253e9eeb1c628c07e1479a509a2e452fde8dff800e88eb8fff5c4b563c623